NCT03016312

Disease Type: Genitourinary
Status: Open

Trial Information

A Phase III Multicenter, randomized, placebo controlled double blind study of Atezolizumab in combination with Enzalutamide versus Enzalutamide alone in patients with metastatic CRPC after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact: